Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs AIM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AYTU 4 – 1 AIM (1 Tie) Matrix Metrics: AYTU 6 – 4 AIM

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin).

  • Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -11724.2% operating margin) and revenue trajectory (+6.4% vs. +4.0% YoY).
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs AIM
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
AIM NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.13
-7.1% 1D
Market Cap $5.9M
TTM Revenue $95,000
Forward P/E 2.0x
Beta / 30D Vol 0.32β · 69% Vol
Unified Composite Score
52.8 / 100 HOLD
Tech 54.0 Fund 57.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.5%), weak momentum, RSI 34
RSI-14: 33.9 · SMA20: $0.16 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (AYTU 4 – 1 AIM)

Columns: Metric · AYTU · AIM
1. Valuation Multiples AIM
Forward P/E 9.2x 2.0x
Trailing P/E 9.2x 2.0x
PEG Ratio N/M 0.71x
EV / Revenue 0.3x 62.4x
2. Growth & Scale AYTU
Revenue Growth (YoY) +6.4% +4.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $95,000
Market Cap $19.6M $5.9M
3. Profitability & Quality AYTU
Gross Margin 64.0% -23.2%
Operating Margin -14.4% -11724.2%
Net Profit Margin -24.8% 0.0%
Return on Equity (ROE) -52.5% -2382.3%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$11M EBITDA
Cash Flow Margin -2.4% N/A
Net Cash / Leverage $4.9M Net Cash $0.27 Book/Sh · -2382.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (6) vs AIM (4)
Institutional Metric AYTU AIM Criterion Row Edge
Market Capitalization
Scale
$19.6M $5.9M Larger Scale AYTU
Trailing P/E Ratio
Valuation
9.2x 2.0x Lower Multiple AIM
Forward P/E Ratio
Valuation
9.2x 2.0x Lower Multiple AIM
Revenue Growth (YoY)
Growth
+6.4% +4.0% Higher Growth AYTU
Operating Margin (TTM)
Profitability
-14.4% -11724.2% Higher Margin AYTU
Net Profit Margin
Profitability
-24.8% 0.0% Higher Margin AIM
Return on Equity (ROE)
Capital Efficiency
-52.5% -2382.3% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($2–$3) 1% ($0–$2) Stronger Trend AYTU
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 0.32β · 69% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 52.8 / 100 (HOLD) Higher Composite AIM
Trailing 12M Revenue (USD)
Operating Scale
$58M $95,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% -23.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 0.71x PEG · 62.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$11M EBITDA ($0.27 Book/Sh · -2382.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AYTU +9.37 pp
AYTU: -11.27% · AIM: -20.64%
3M Horizon AYTU +19.66 pp
AYTU: -23.31% · AIM: -42.97%
6M Horizon AYTU +53.49 pp
AYTU: -13.81% · AIM: -67.3%
1Y Horizon AYTU +78.75 pp
AYTU: -12.14% · AIM: -90.89%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue AIM Revenue AYTU Op. Margin AIM Op. Margin Margin Leader
FY2019 $10M $0M -230.1% -8887.9% AYTU
FY2020 $30M $0M -76.5% -9295.7% AYTU
FY2021 $70M $0M -89.7% -13954.1% AYTU
FY2022 $100M $0M -113.7% -14129.8% AYTU
FY2023 $110M $0M -15.9% -15800.0% AYTU
FY2024 $70M $0M -2.4% -11630.6% AYTU
FY2025 $70M $0M -11.8% -13254.5% AYTU
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AIM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
AIM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.9M market capitalization and -11724.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs AIM Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin). Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -11724.2% operating margin) and revenue trajectory (+6.4% vs. +4.0% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with AIM at +4.0% YoY revenue growth and +0.0% YoY earnings growth on $95,000 TTM revenue (-23.2% gross margin, -11724.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while AIM shifted N/A. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AIM.

AIM screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas AIM trades at 2.0x Forward P/E, 2.0x Trailing P/E, 0.71x PEG, and 62.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus AIM (-2382.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, AIM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.